Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02938624
Recruitment Status : Recruiting
First Posted : October 19, 2016
Last Update Posted : May 19, 2017
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Jair Bar, M.D., Ph.D., Sheba Medical Center

Brief Summary:

A single arm, phase I, dose escalation trial and expansion cohort, examining the safety and feasibility of neoadjuvant pembrolizumab treatment for early resectable NSCLC patients.

Hypothesis: The investigators hypothesize that response rate to neo-adjuvant pembrolizumab will be higher than the response rate of advanced NSCLC patients.


Condition or disease Intervention/treatment Phase
Non Small Cell Lung Carcinoma Stage I Stage II Drug: Pembrolizumab 200 mg IV single dose Drug: Pembrolizumab 200 mg IV twice interval 21 days Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d Drug: Pembrolizumab 100 mg I.V single dose Procedure: Surgical resection of tumor Phase 1

Detailed Description:

16-28 patients with apparently operable NSCLC, clinically staged I-II with a resectable tumor would be recruited. Recruitment would be based on clinical assessment by a qualified Thoracic surgeon, with the appreciation that some of the recruited patients would eventually be deemed to be non-operable, or with a non-resectable disease, or to harbor a diagnosis different from NSCLC.

Screen of consenting patients would include a diagnostic biopsy that includes core needle biopsy procedure. Fresh as well as formalin fixed paraffin embedded baseline tumor samples will be obtained according to common Standard Operating Procedures. Specimens would be processed as per pathology standard of care and two cores or more will be utilized later for the research study.

A patient recruited after a previous diagnostic biopsy, would be eligible for the trial only if willing to undergo a repeat diagnostic procedure as above. Processing of biopsy material will be similar regardless if it is first or second biopsy.

Trial treatment will commence only following pathological confirmation of NSCLC, complete staging including CT-PET and brain imaging, and positive pre-op cardiac and pulmonary assessment.

Study schedule Dose levels of this study are defined by dose of drug as well as number of treatments and required interval from last treatment to surgery. At least 3 subjects in a dose cohort must complete the dose limiting toxicity (DLT) evaluation period before dosing is initiated at the next higher dose level. Only toxicities occurring during the DLT period will be considered as DLTs and utilized to inform dose escalation decisions. The DLT period starts with the first dose of pembrolizumab till 30 days post-surgery.

Cohorts consists of 3-6 subjects per dose level, to be treated with study therapy following a 3+3 schema.

Dose escalation will proceed between cohorts according to a modified "3+3 design," as explained in the following scheme. Dose-limiting toxicity (DLT) is defined below and is confined in time as defined above. As a safety feature, a new dosing/schedule level will open only after the end of 30 post-operative days of the last patient in the previous cohort. If cohort one will be found to be too high as RP2D/schedule, the next patients will be treated at a dose/schedule level minus one. Only one step of dose reduction is planned.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anti PD-1 Neo-adjuvant Treatment for Early Stage NSCLC - Phase I Study
Actual Study Start Date : January 7, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: cohort1
Pembrolizumab 200 mg I.V single dose
Drug: Pembrolizumab 200 mg IV single dose
Pembrolizumab 200 mg IV single dose, 21 days later surgery
Other Name: keytruda

Procedure: Surgical resection of tumor
Surgical resection of tumor by any of the acceptable procedures
Other Name: Lobectomy/pneumonectomy/bi-lobectomy

Experimental: Cohort II
Pembrolizumab 200 mg I.V Twice interval 21 days
Drug: Pembrolizumab 200 mg IV twice interval 21 days
Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
Other Name: keytruda

Procedure: Surgical resection of tumor
Surgical resection of tumor by any of the acceptable procedures
Other Name: Lobectomy/pneumonectomy/bi-lobectomy

Experimental: Cohort III
Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Other Name: keytruda

Procedure: Surgical resection of tumor
Surgical resection of tumor by any of the acceptable procedures
Other Name: Lobectomy/pneumonectomy/bi-lobectomy

Experimental: COHORT -1
Pembrolizumab 100 mg I.V single dose
Drug: Pembrolizumab 100 mg I.V single dose
Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
Other Name: keytruda

Procedure: Surgical resection of tumor
Surgical resection of tumor by any of the acceptable procedures
Other Name: Lobectomy/pneumonectomy/bi-lobectomy




Primary Outcome Measures :
  1. Dose limiting toxicities [ Time Frame: 24 months ]
    Protocol defined dose limiting toxicities, aiming to identify RP2D=Recommended Phase 2 Dose/schedule.

  2. Percentage of residual viable tumor cells [ Time Frame: 24 months ]
    Percent residual viable tumor cells in post-treatment pathologic specimen

  3. Percent change in tumor volume [ Time Frame: 24 months ]
    Volumetric CT assessment at CT scan performed prior to surgical resection of tumor, relative to base line CT scan.


Secondary Outcome Measures :
  1. Median time-to-recurrence. [ Time Frame: 48 Months ]
    Median time-to-recurrence of disease in NSCLC patients treated with neo-adjuvant pembrolizmab and surgical resection of tumor, assessed by Kaplan-Meier method.

  2. Median Overall survival. [ Time Frame: 60 months ]
    Median Overall survival of NSCLC patients treated with neo-adjuvant pembrolizmab and surgical resection of tumor, assessed by Kaplan-Meier method.


Other Outcome Measures:
  1. Change in percentage of cells expressing PDL1 in tumors with treatment [ Time Frame: 24 Months ]
    Comparing pre and post pembrolizumab.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical or pathological diagnosis of early resectable NSCLC stage I-II (AJCC version 7).
  2. Have measurable tumor of a least one cm in its largest diameter.
  3. Clinically assessed to be a candidate for curative intent lobectomy or larger procedure (e.g. bilobectomy, pneumonectomy, lobectomy with segmentectomy, etc).
  4. Is willing to undergo a procedure aimed to collect tumor tissue for pathologic diagnosis and for research correlative studies.
  5. Be willing and able to provide written informed consent/assent for the trial.
  6. Be > 18 years of age on day of signing informed consent.
  7. Have a performance status of 0 or 1 on the ECOG Performance Scale.
  8. Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 10 days of treatment initiation.

    Table 1: Adequate Organ Function Laboratory Values System Laboratory Value Hematological Absolute neutrophil count (ANC) >=1,500 /mcL Platelets>=100,000 / mcL Hemoglobin>= 9 g/dL or >=5.6 mmol/L RenalSerum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) <=1.5 X upper limit of normal (ULN) OR >=60 mL/min for subject with creatinine levels > 1.5 X institutional ULN Hepatic Serum total bilirubin <=1.5 X ULN OR Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 ULN AST (SGOT) and ALT (SGPT) <= 2.5 X ULN OR Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants <=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants aCreatinine clearance should be calculated per institutional standard.

  9. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  10. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  11. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion Criteria:

  1. Severe lung emphysema with a significantly elevated risk of dangerous complications from a biopsy of a lung lesion.
  2. Predicted post-operative (PPO)-FEV1 or PPO-DLCO < 30% (as calculated based on patient's age, sex, weight, height and planned operation).
  3. Has a known diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  4. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., <= Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy (besides as part of a curative treatment for a different malignancy, completed 5 years or more prior recruitment to study).
  6. Has a known additional active malignancy. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, low grade bladder TCC or in situ cervical cancer that has undergone potentially curative therapy. History of other malignancies can be permitted provided at least five years have passed since the completion of a potentially curative therapy.
  7. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
  8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
  9. Has an active infection requiring systemic therapy.
  10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  12. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  14. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  15. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  16. Has a known history of active TB (Bacillus Tuberculosis).
  17. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02938624


Contacts
Layout table for location contacts
Contact: Jair Bar, MD PHD 972-3530-7096 Yair.Bar@sheba.health.gov.il
Contact: Aliza Ackerstein, Msc 972546853835 aliza.ackerstein@sheba.health.gov.il

Locations
Layout table for location information
Israel
Sheba Medical Center Recruiting
Ramat Gan, Israel, 52621
Contact: Dana Botser       dana.botser@sheba.health.gov.il   
Principal Investigator: Jair Bar, MD-PhD         
Sponsors and Collaborators
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Sheba Medical Centre Jair, MD PHD Chaim Sheba Medical Center

Layout table for additonal information
Responsible Party: Jair Bar, M.D., Ph.D., Deputy Director, Institute of Oncology, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT02938624     History of Changes
Other Study ID Numbers: 3282/16SMC
First Posted: October 19, 2016    Key Record Dates
Last Update Posted: May 19, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents